AIS

[Terliso]

BUSINESS SUMMARY   

Antares Pharma, Inc. operates as a specialty drug delivery/pharmaceutical company providing drug delivery systems for pharmaceuticals. The company's technology platforms include transdermal gels, fast-melt oral tablets, disposable minineedle injection systems, and reusable needle-free injection systems. Its transdermal drug delivery platform develops gels, which deliver medication with less potential for skin irritation, and avoiding the initial gastrointestinal and liver uptake problems of some orally ingested drugs. The company's fast-melt oral disintegrating tablets are designed to help patients experiencing difficulty in swallowing pills, tablets, or capsules. Its injection device platform features reusable needle-free injectors, which deliver precise medication doses through pressurized liquid penetration of the skin without a needle; disposable minineedle injectors, which are designed to provide subcutaneous injection capabilities with reduced discomfort and safety of a shielded needle; and emerging vaccine intradermal injectors. The company was incorporated in 1979 and was formerly known as Medi-Ject Corporation. Antares Pharma is headquartered in Exton, Pennsylvania.


NEWS: Tue, Dec 13, 2005

• Antares late-stage study of gel to start in 2006
http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh26881_2005-12-13_12-22-05_wen6117_newsml
     
• Antares Reports Progress with Anturol(TM) Oxybutynin Gel
http://biz.yahoo.com/prnews/051213/nytu049.html?.v=35


--- Breakout from Symmetrical Triangle 3 year  Pattern

[Terliso]

NEWS, NEWS, NEWS...

*** Dawson James Securities Upgrades Antares Pharma to Strong Buy With $4.00 Price Target.
*** Positive Phase II Clinical Trial Results Announced by Antares Pharma.
*** Antares Completes the Phase II Clinical Trial for Anturol(TM)
http://finance.yahoo.com/q/h?s=AIS

[eliteG]

good eye Terlisa(as always)  .. AIS came up on my scans Thursday.  I like that they have a "real" product that should see application right away... their mkt cap does not reflect that.. yet    Looks very strong technically.

[eliteG]

this is what I jotted down Thurday after mkt close.. 

AIS - 1.55, drug delivery, mkt cap 65million, 30million float, EPS -.23,  recent $11m priv placement and upgrade to $4, 1.68 is a breakout, strong move from bunched mvg avg(9,20,50) 4x avg volume may be a flag break, long-term confirms 1.68 ascending triangle breakout resis 3, hot drug Antural for overactive bladder recent positive phase II, phase 3 second half of 2006

[la-onda]

fyi:
AIS: Closes $11M PIPE: Common Stock + Warrants
Monday , March 06, 2006 09:14 ET

On March 3, 2006, Antares Pharma Inc (amex:AIS) completed the Private Placement and sold 8,770,000 shares of its common stock at a price of $1.25 per share and issued warrants to purchase 6,577,500 shares of its common stock with an exercise price of $1.50 per share. The Private Placement resulted in gross proceeds of $10,962,500 to the Company before deducting the placement agents' fees and expenses of approximately $993,338, as well as the other transaction expenses payable by the Company. SCO Securities LLC and Dawson James Securities, Inc. acted as the Company's placement agents for this transaction.
&
AIS: Dawson James Ups to Strong Buy; Analyst Notes
Thursday , March 16, 2006 09:12 ET
Issuer: Antares Pharma Inc (AMEX: AIS)
Analyst Firm:  Dawson James Securities
Ratings Action: UPGRADE
Current Rating: Strong Buy
Analyst Comments: According to the firm, FDA approval for Bio-E-Gel is expected in Q4 2006 by Antares Pharma development partner Biosante Pharmaceuticals (Nasdaq: BPA), who recently filed the NDA. In addition, based on the recent strong Phase II results for Anturol in overactive bladder syndrome patients, Antares Pharma expects to begin Phase III in Q3 2006 under 505(b)(2) rules.

[setravis]

Strong Buy.....
MACD bouncing off center , RSI turning north bound.
Micro-Cap growth company in the health care sector, produces and markets specialty drug delivery/pharmaceutical products.


Technicals
Last Price Quote is:
1.64%above 13-day EMA
4.81%above 50-day EMA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $41.52 

[Terliso]

Some buying upgrades for AIS

[Terliso]

Trend is your friend

[Terliso]

 

[setravis]

Volume Alert...We have the Golden Cross !
Updated chart look

52wk Range: 0.29 - 1.21
Volume: 11,294,776
Avg Vol (3m): 296,298

Technicals
Last Price Quote is:
41.69%above 13-day MA
71.23%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $41.52 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/06/2009
Last Analyst Rating: Outperform